Dr. Lindsey Fitzgerald
Claim this profileHuntsman Cancer Institute/University of Utah
Area of expertise
Lymphoma
Lindsey Fitzgerald has run 3 trials for Lymphoma. Some of their research focus areas include:
Chronic Lymphocytic Leukemia
Lindsey Fitzgerald has run 2 trials for Chronic Lymphocytic Leukemia. Some of their research focus areas include:
Affiliated Hospitals
Huntsman Cancer Institute/University Of Utah
George E. Wahlen Department Of Veterans Affairs Medical Center
Clinical Trials Lindsey Fitzgerald is currently running
Nicotinamide
for Chronic Lymphocytic Leukemia and Skin Cancer
This is a randomized, phase II, double-blind, placebo-controlled trial with planned crossover to the intervention arm after 1 year. Consenting patients with CLL who have had at least one NMSC diagnosed in the past year will be randomized to receive either oral nicotinamide 500 mg twice daily (BID) for 1 year or oral placebo 1 tablet twice daily for 1 year. Patients will be stratified according to CLL therapy and the number of prior NMSC. At the end of 1 year, patients will undergo dermatologic examination and the number of new NMSC will be quantified. The number of patients who develop new NMSC in each arm will be documented. At this time, patients will be unblinded and all patients will receive Nicotinamide 500 mg BID for an additional year. At the end of this second year, patients will again undergo dermatologic examination, and the number of new NMSC will be quantified. The number of patients who develop NMSC will be documented. Skin biopsies will be taken for correlative studies. Enrollment will be split into two parts separated by an interim analysis. Part 1 will accrue 40 patients: 20 to each arm. After 40 patients have completed their 12 month visit an interim futility analysis will be conducted prior to recruiting more patients. The study will stop if the difference in the number of patients with NMSC between control and treatment arms is 0 or less (i.e., absolutely no evidence that the treatment is better than control). If the trial is not stopped, the investigators will proceed with Part 2 and recruit 46 more patients.
Recruiting
0 awards
Phase 2
8 criteria
Venetoclax + Obinutuzumab
for Leukemia
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Starting treatment with the venetoclax and obinutuzumab early (before patients have symptoms) may have better outcomes for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma compared to starting treatment with the venetoclax and obinutuzumab after patients show symptoms.
Recruiting
2 awards
Phase 3
1 criteria
More about Lindsey Fitzgerald
Clinical Trial Related
3 years of experience running clinical trials · Led 4 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Lindsey Fitzgerald has experience with
- Nicotinamide
- Placebo
- Cyclophosphamide
- Oral Azacitidine
- Prednisone
- Rituximab
Breakdown of trials Lindsey Fitzgerald has run
Lymphoma
Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Lindsey Fitzgerald specialize in?
Lindsey Fitzgerald focuses on Lymphoma and Chronic Lymphocytic Leukemia. In particular, much of their work with Lymphoma has involved MYC positive patients, or patients who are BCL2 positive.
Is Lindsey Fitzgerald currently recruiting for clinical trials?
Yes, Lindsey Fitzgerald is currently recruiting for 3 clinical trials in Salt Lake City Utah. If you're interested in participating, you should apply.
Are there any treatments that Lindsey Fitzgerald has studied deeply?
Yes, Lindsey Fitzgerald has studied treatments such as Nicotinamide, Placebo, Cyclophosphamide.
What is the best way to schedule an appointment with Lindsey Fitzgerald?
Apply for one of the trials that Lindsey Fitzgerald is conducting.
What is the office address of Lindsey Fitzgerald?
The office of Lindsey Fitzgerald is located at: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah 84112 United States. This is the address for their practice at the Huntsman Cancer Institute/University of Utah.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.